Objective-Transforming growth factor-β-activated kinase 1 (TAK1) is a mitogen-activated protein 3-kinase and an AMPactivated protein kinase (AMPK) kinase in some cell types. Although TAK1 −/− mice display defects in developmental vasculogenesis, the role of TAK1 in endothelial cells has not been investigated in detail. Approach and Results-TAK1 downregulation (small interfering RNA) in human endothelial cells attenuated proliferation without inducing apoptosis and diminished endothelial cell migration, as well as tube formation. Cytokine-and vascular endothelial growth factor (VEGF)-induced endothelial cell sprouting in a modified spheroid assay were abrogated by TAK1 downregulation. Moreover, VEGF-induced endothelial sprouting was impaired in aortic rings from mice lacking TAK1 in endothelial cells (TAK ΔEC ). TAK1 inhibition and downregulation also inhibited VEGF-stimulated phosphorylation of several kinases, including AMPK. Proteomic analyses revealed that superoxide dismutase 2 (SOD2) expression was reduced in TAK1-deficient endothelial cells, resulting in attenuated hydrogen peroxide production but increased mitochondrial superoxide production. Endothelial cell SOD2 expression was also attenuated by AMPK inhibition and in endothelial cells from AMPKα1 −/− mice but was unaffected by inhibitors of c-Jun N-terminal kinase, p38, extracellular signal-regulated kinase 1/2, or phosphatidylinositol 3-kinase/Akt. Moreover, the impaired endothelial sprouting from TAK ΔEC aortic rings was abrogated in the presence of polyethylene glycol-SOD, and tube formation was normalized by the overexpression of SOD2. A similar rescue of angiogenesis was observed in polyethylene glycol-SOD-treated aortic rings from mice with endothelial cell-specific deletion of the AMPKα1. Conclusions-These results establish TAK1 as an AMPKα1 kinase that regulates vascular endothelial growth factorinduced and cytokine-induced angiogenesis by modulating SOD2 expression and the superoxide anion:hydrogen peroxide balance. (Arterioscler Thromb Vasc Biol. 2013;33:2792-2799.)
T he transforming growth factor (TGF)-β-activated kinase 1 (TAK1) is a mitogen-activated kinase kinase kinase activated by TGF-β, tumor necrosis factor-α (TNF-α), and other cytokines including interleukin-1β (IL-1β), 1,2 and thus it acts as a key player in proinflammatory cytokine signaling. 3 TAK1 has also been proposed to act as an AMP-activated protein kinase (AMPK) kinase in some cells 4 as it is activated by well-established triggers of AMPK activity, such as 5-aminoimidazole-4-carboxamide riboside (AICAR), or ischemia. 5 However, recent reports place the AMPK upstream of TAK1 in inflammatory signaling pathways, indicating a reciprocal interaction between both kinases. 6, 7 In endothelial cells, the AMPK can be activated by vascular endothelial growth factor (VEGF), 8 adiponectin, 9 as well as by hypoxia 10 and other angiogenic factors. 11 Moreover, dominant-negative AMPK or the inclusion of small interfering RNA (siRNA) directed against the AMPK inhibits angiogenesis in Matrigel plugs impregnated with basic fibroblast growth factor 10 or VEGF. 11 Although there is only limited information on the consequences of AMPK deletion on angiogenesis or vascular repair, 12 the deletion of the Tak1 gene causes embryonic lethality, which is associated with vascular abnormalities including dilated blood vessels and the loss of smooth muscle differentiation. 13 When targeted in endothelial cells, the loss of TAK1 impairs angiogenesis at the same time as increasing cell death and vessel regression at embryonic day 10.5. 14 How TAK1 regulates vessel formation has yet to be elucidated.
Given the limited information about the events linking TAK1 with angiogenesis, we set out to study TAK1 signaling in growth factor-stimulated and cytokine-stimulated endothelial cells and the potential role of AMPK activation.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Animals
Mice (C57BL/6x, low-density lipoprotein receptor −/− ) harboring endothelial cell-specific TAK1 deletion (TAK ΔEC ) were generated by breeding TAK1 loxP/loxP mice 15 (kindly provided by Shizuo Akira, Osaka, Japan) with low-density lipoprotein receptor −/− mice. The endothelial TAK1 was deleted after breeding this strain with transgenic mice expressing the Cre recombinase under the control of the VE-cadherin promoter. Endothelial-specific AMPKα1 −/− mice were generated by breeding floxed AMPKα1 mice (provided by B. Viollet, Paris, France) with VE-cadherin-Cre mice, both strains are in the C57BL/6 background. Animals were housed in conditions that conform to the guidelines for the housing and care of animals in directive 2007/526/EC (EU 2007) . For the isolation of organs, mice were euthanized using 4% isoflurane in air and subsequent exsanguination.
Statistics
Values are expressed as the mean±SEM, and statistical evaluation was performed using Student t test for unpaired data, 1-way ANOVA, or ANOVA for repeated measures followed by a Newman-Keuls t test, where appropriate. Values of P<0.05 were considered statistically significant.
Results

Role of TAK1 in Endothelial Cell Proliferation, Migration, and Angiogenesis
The siRNA-mediated downregulation of TAK1 in human endothelial cells ( Figure 1A ) significantly attenuated proliferation in the presence of 5% fetal calf serum ( Figure 1B ). Although the deletion of TAK1 sensitizes some cells to agonist-induced apoptosis, 16 and increased TNF-α-induced apoptosis after TAK1 deletion has been linked with impaired vasculogenesis, 14 there was no effect of TAK1 downregulation on either the expression of annexin V or the cleavage of caspase 3 under the conditions studied ( Figure I in the online-only Data Supplement). TAK1 downregulation also attenuated endothelial cell migration in a scratch-wound assay ( Figure 1C ), as well as the ability to form tube-like structures on Matrigel. The defect in tube formation was evident in cells cultured in the absence and in the presence of VEGF ( Figure 1D ). The downregulation of TAK1 also attenuated basal and VEGF-induced sprouting in a modified spheroid assay ( Figure 1E ).
In mouse abdominal skeletal muscle, TAK1 was expressed clearly in small vessels where it colocalized with CD31 and smooth muscle actin (Figure 2A) . Similarly, in the aorta, TAK1 was detected in endothelial cells and in vascular smooth muscle cells ( Figure 2B ). Thus, to determine the role of TAK1 in angiogenesis, endothelial cell sprouting (CD31-positive cells) was assessed in aortic rings from wild-type mice and animals lacking catalytically active TAK1 15 specifically in endothelial cells (TAK ΔEC ). Both the sprout number and the total sprout length were reduced markedly in aortic rings from TAK ΔEC mice under basal conditions and after stimulation with VEGF ( Figure 2C ).
VEGF Stimulates TAK1 and AMPK in Endothelial Cells
Next, we determined the consequences of inhibiting TAK1 on VEGF signaling. In solvent-treated cells, VEGF elicited the phosphorylation of the c-Jun N-terminal kinase (JNK), p38 mitogen activated protein kinase, extracellular signal-regulated kinase (ERK)1/2, and Akt, but responses were attenuated markedly in the presence of the TAK1 inhibitor oxozeaenol ( Figure 3A) . Similar effects were observed in cells treated with Figure 3B ). The TAK inhibitor had no direct effect on the VEGF-induced phosphorylation of the VEGF receptor 2 (VEGFR2) ( Figure 3C ), indicating that there was no off-target effect on the initiation of VEGF signaling. The AMPK has been implicated in VEGF-induced angiogenesis 10, 11 and given that TAK1 has been characterized as an AMPK kinase in some cells, we determined whether this was also the case in endothelial cells. Although VEGF stimulated the phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase in solvent-treated cells, the TAK1 inhibitor prevented both these responses ( Figure 3D ).
TAK1 Regulates Cytokine-Induced Angiogenesis
IL-1β and TNF-α are well-characterized activators of TAK1 2,3 and inducers of angiogenesis. [17] [18] [19] However, whether cytokineinduced angiogenesis is dependent on TAK1 is not known. Although TGF-β was largely ineffective, IL-1β and TNF-α elicited the activation of JNK and p38 kinase in endothelial cells, responses that were inhibited in the presence of oxozeaenol ( Figure 4A ). To link these findings to angiogenesis, the effects of IL-1β and TNF-α were studied in the modified spheroid sprouting assay. Both cytokines stimulated endothelial cell sprouting in spheroids transfected with a control siRNA, but had little effect in endothelial cells treated with a TAK1 siRNA ( Figure 4B ).
TAK1 Regulates Reactive Oxygen Species Production in Endothelial Cells
To identify TAK1-regulated proteins that are involved in cytokine-mediated angiogenesis, human endothelial cells treated with control siRNA or siRNA directed against TAK1 were stimulated with solvent or IL-1β. IL-1β was chosen for these studies as it elicited the strongest oxozeaenol-sensitive signaling response in the cells studied. Using an isotope-coded protein labeling strategy in combination with mass spectrometry, 12 potential TAK1-regulated proteins were identified ( Table I in the online-only Data Supplement). Of these, manganese superoxide dismutase (SOD2) was of particular interest as the production of reactive oxygen species (ROS) in response to VEGFR2 activation is thought to be required for angiogenesis. 20 It was possible to confirm the results of the proteomics analyses in as much as cultured pulmonary endothelial cells from TAK ΔEC mice expressed lower levels of SOD2 than cells from the wild-type mice ( Figure 5A ). There was, however, no significant difference in the expression of SOD1, SOD3, peroxiredoxin-1, or catalase in endothelial cells from wild-type or TAK ΔEC mice. SOD2 mRNA levels (reduction of 43±3%; P<0.05; n=4 different cell batches) and protein expression ( Figure 5B ) were also decreased in human endothelial cells after TAK1 downregulation using siRNA. The TAK1 siRNAmediated downregulation of SOD2 could not be mimicked by the JNK inhibitor SP600125, the p38 inhibitor SB203580, the ERK1/2 inhibitor U0126, or the phosphatidylinositol 3-kinase-Akt inhibitor wortmannin. The AMPK inhibitor, compound C, however, decreased SOD2 expression, an effect that was not further affected by TAK1 downregulation ( Figure  5C ). To determine which AMPK subunit was involved in regulating SOD2 expression, endothelial cells were isolated from AMPKα1 −/− and AMPKα2 −/− mice and their respective wildtype littermates. SOD2 levels were comparable in wild-type and AMPKα2 −/− mice but significantly attenuated in endothelial cells from AMPKα1 −/− mice ( Figure 5D ).
To assess the consequences of TAK1 deletion on the endothelial production of ROS, H 2 O 2 production was assessed in Amplex Red-loaded cells. H 2 O 2 production was lower in endothelial cells from TAK ΔEC mice than wild-type mice under basal conditions, as well as after stimulation with VEGF ( Figure 5E ). SOD2 is a critical defense enzyme located in the mitochondrial matrix. 21 To understand the functional consequences of the decrease in SOD2, we next investigated the consequences of TAK1 deletion on mitochondrial number and function. No difference in the number of mitochondria (as determined by mitotracker intensity) could be detected in endothelial cells from wild-type and TAK ΔEC mice ( Figure 5F ). However, there was a loss of mitochondrial membrane potential indicated by a shift from red to green fluorescence in JC1-loaded cells lacking TAK1 Figure 5G ). TAK1 deficiency was also associated with an increase in basal and VEGF-stimulated mitochondrial superoxide production, assessed using the MitoSOX reagent and subsequent flow cytometry ( Figure 5H ).
TAK1-Dependent Angiogenesis Requires SOD2 Activity
To demonstrate a causal link among TAK1, AMPKα1, and SOD2 in angiogenesis, we reassessed endothelial cell sprouting in the presence or absence of polyethylene-glycolyated (PEG)-SOD, which increases cellular SOD activity and protects against the damaging effects of ROS. 22 As before, endothelial sprouting from aortic rings from TAK ΔEC mice was attenuated under basal conditions, as well as in the presence of VEGF. Remarkably, the inclusion of PEG-SOD normalized basal and VEGF-induced sprouting ( Figure 6A) . Similar effects were observed in human endothelial cell spheroids after the downregulation of TAK1 ( Figure II in the onlineonly Data Supplement). In line with the finding that only the mitochondrial SOD2 isoform is affected by TAK1, the overexpression of SOD2 abrogated the disturbed tube formation in TAK1-deleted endothelial cells ( Figure III in the onlineonly Data Supplement). The overexpression of SOD1 was without effect. Basal and VEGF-induced endothelial cell sprouting was attenuated in aortic rings from animals lacking the AMPKα1 subunit specifically in endothelial cells versus their wild-type littermates. The defective endothelial cell sprouting in the rings lacking endothelial AMPKα1 was also rescued by PEG-SOD ( Figure 6B ).
Discussion
The results of the present study indicate that TAK1 acts as an AMPKα1 kinase in endothelial cells and positively regulates VEGF-induced, TNF-α-induced, and IL-1β-induced angiogenesis by increasing the expression of the antioxidative mitochondrial enzyme, SOD2. Indeed, superoxide production and the mitochondrial membrane potential were reduced in the absence of TAK1, and the impaired endothelial cell sprouting from aortic rings from TAK ΔEC and AMPKα1 ΔEC mice was rescued in the presence of PEG-SOD. The global deletion of TAK1 impairs embryonic development in C. elegans, 23 zebrafish, and mice. 13 Both the global and endothelial-specific deletions of TAK1 result in vascular malformation, dilated capillaries, and defects in vascular stabilization, 14 and correlate well with the phenotype of endothelial cell-specific TGF-β type II receptor conditional mutants. 24 In addition to its role in vascular development, TAK1 has also been implicated in the TGFβ-induced regulation of matrix metalloproteinase-9 and tumor vascularization as the suppression of TAK1 signaling by a dominant-negative TAK1 mutant reduced tumor growth and formation of lung metastases in severe combined immunodeficiency mice. 25 The results of the present investigation confirm that the inhibition/downregulation of TAK1 in endothelial cells inhibits endothelial cell proliferation, migration, and sprouting. These effects could not be linked to the induction of apoptosis, assessed as changes in annexin V levels and caspase 3 cleavage, although TAK1 is known to prevent TNF-α-induced death in other cell types. 14, 26 Endothelial cell function and angiogenesis are tightly regulated by growth factors, particularly by VEGF. The VEGF signaling pathway in endothelial cells is complex but involves the activation of Akt, ERK1/2, JNK, p38, and AMPK. 27 Determining whether TAK1 is part of a signaling cascade is complicated by the fact that the activity of the kinase is regulated by its association with regulator/activating proteins and phosphorylation, as well as by ubiquitination and methylation. 3 Therefore, we used a combination of a pharmacological TAK1 inhibitor, that is, (5Z)-7-oxozeaenol, and siRNA-mediated TAK1 downregulation to study the role of the kinase in endothelial cell function. Using these tools it was possible to demonstrate that TAK1 activity is required for the VEGF-induced phosphorylation of JNK, p38, ERK1/2, and Akt. These effects could not be attributed to an indirect effect on the VEGF receptor as VEGFR2 expression and its phosphorylation were unaffected by TAK1 inhibition.
The AMPK is activated by phosphorylation on Thr172, generally as a result of the inhibition of the protein phosphatases PP1 and PP2A or the direct phosphorylation of the enzyme by an upstream kinase (for review see Carling et al 28 ). The best studied AMPK kinases are the Ca 2+ /calmodulindependent protein kinase kinase β and liver kinase B1, with TAK1 being characterized as a third AMPK kinase in some cells. 4 Indeed, TAK1 is activated by ischemia and substances such as AICAR, which are well-established AMPK activators. 5 Currently no information is available on a potential link between TAK1 and Ca 2+ /calmodulin-dependent protein kinase kinase β, but the deletion of TAK1 largely prevented the activation of liver kinase B1 and AMPK in mouse embryo fibroblasts indicating that more classical AMPK kinases may be downstream of TAK1. 5 The situation is, however, currently confused as some reports place the AMPK upstream of TAK1 in inflammatory signaling pathways, indicating a more complicated interaction between the kinases. 6, 7 Our investigation indicates that the AMPK is a TAK1 substrate in growth factor-stimulated endothelial cells as TAK1 inhibition prevented VEGF-induced phosphorylation of the AMPK, as well as its downstream target acetyl-CoA carboxylase.
TAK1 has been referred to as the most widely used MAP kinase kinase kinase in the immune system 29 and regulates the activity of several kinase pathways, including the nuclear factor κB and Akt pathways 30 in addition to that of the AMPK. TAK1 is probably best linked to inflammation, which is closely linked to angiogenesis. Indeed, in endothelial cells, inflammatory cytokines, such as IL-1β, are known to regulate the expression of proangiogenic factors 17 and to induce endothelial tube formation via JNK and p38 activation. 19 Moreover, the administration of IL-1-receptor antagonists inhibits tumor growth and neovascularization. 31 Fitting with our observation that the VEGF-induced activation of JNK and p38 was attenuated by TAK1 inhibition or downregulation, the same pathways were also regulated by TAK1 in IL-1β-stimulated and TNF-α-stimulated endothelial cells. Similarly, cytokine-induced endothelial sprouting was markedly reduced in TAK1 siRNA-treated cell spheroids.
To determine the molecular mechanisms linking TAK1 activation with angiogenesis, we determined changes in the protein expression profile in IL-1β-treated endothelial cells after siRNA-mediated TAK1 downregulation. Of the proteins that were altered by >30%, most were involved in redox regulation. We focused on SOD2 as it was also attenuated by AMPK inhibition and was most markedly affected in TAK1 siRNA-treated human endothelial cells and in endothelial cells from TAK ΔEC and AMPKα1 ΔEC mice. SOD2 is a mitochondrial enzyme that dismutates the O 2 − generated by the respiratory chain to oxygen and H 2 O 2 . Therefore, a decrease in its expression would be expected to attenuate cellular H 2 O 2 levels and increase those of O 2 − , which is what was observed in endothelial cells from TAK ΔEC mice, accompanied by a decrease in the mitochondrial membrane potential. Low levels of either intracellular or extracellular ROS, in particular H 2 O 2 , are thought to be essential for angiogenesis. 20, 32 Mitochondria are crucially involved in VEGF-induced ROS production, 33 and inhibition of mitochondrial ROS formation attenuates angiogenesis in endothelial cells. 34 There is circumstantial evidence that TAK1 and the AMPK are involved in the regulation of this process as an AMPK-PTEN (phosphatase and tensin homolog deleted from chromosome 10) pathway was reported to determine ROS formation stimulated by the TAK1 activator, TNF-α. 35 However, H 2 O 2 can inhibit protein phosphatases such as PTEN/PP2A, 36 which are known regulators of the AMPK 37 -a process that may in turn increase AMPK activity.
We also found that AMPKα1 deletion reduced endothelial SOD2 expression. Ours is not the first report that AMPKα1 regulates SOD2 expression as the siRNA-mediated downregulation of AMPKα1 in human endothelial cells decreased SOD2 levels, reduced cell proliferation, and increased the accumulation of ROS and apoptosis. 38 Moreover, the AMPK activator metformin has been reported to increase angiogenesis via the regulation of SOD2 expression and activity. 39 Also, AICAR increases SOD2 expression in progenitor cells from streptozotocin-induced diabetic mice and rescues their angiogenic function. 40 The expression of SOD2 is regulated by a series of transcription factors, including nuclear factor κB and Forkhead box class O transcription factors. 21 The deletion of both TAK1 and AMPKα1 attenuated SOD2 expression in endothelial cells, and both kinases have been reported previously to target nuclear factor κB 6 and Forkhead box class O. 30, 41 There are strong links between SOD2 activity and angiogenesis as the mitochondrial generation of H 2 O 2 by SOD2 has been reported previously to promote endothelial cell sprouting. Moreover, SOD2 overexpression increases H 2 O 2 -dependent blood vessel formation in the chicken chorioallantoic membrane. 42 It was possible to make a direct link between the endothelial deletion of TAK1 or AMPKα1 and the downregulation of SOD2 as the defective angiogenesis observed in aortic rings and endothelial cells from TAK ΔEC and AMPKα1 ΔEC mice could be rescued by both PEG-SOD and the overexpression of SOD2.
Taken together, the results of this study indicate that TAK1 is a signaling intermediate in the VEGF-and cytokine-signaling cascades upstream of p38, JNK, ERK1/2, Akt, and AMPK activation. The downregulation or inactivation of TAK1 attenuated endothelial cell migration and angiogenesis, phenomena that could be attributed to the downregulation of SOD2, and the subsequent inadequate conversion of O 2 − to Figure 6 . Rescue of angiogenesis in aortic rings from transforming growth factor-β-activated kinase 1 (TAK1 DEC ) and AMPKα1 DEC mice by polyethylene-glycolyated superoxide dismutase 2 (PEG-SOD). Endothelial cell sprouting from aortic rings from (A) wildtype (WT) and TAK ΔEC littermates and (B) WT and AMPKα1 ΔEC littermates in the presence of solvent (Sol) or vascular endothelial growth factor (VEGF; 10 ng/mL) and the absence and presence of PEG-SOD (100 U/mL); green=CD31, bar=1 mm. The graphs summarize data from 4 to 5 different animals; *P<0.05, **P<0.01, and ***P<0.001 as indicated. AMPK indicates AMP-activated protein kinase. H 2 O 2 , and could be rescued by PEG-SOD or SOD2 overexpression. We speculate that this mechanism contributes to the vascular complications associated with pathological conditions, such as diabetes mellitus, where TAK1 and AMPK activity are disturbed. 43 
